0090sek
-2,3 %
Date:2024-04-23Time:17:29:31Latest report:Q4-2023List:First NorthTicker:DIABIO
Market Cap:4 msekEnterprise Value:1 msekNet Sales:0,02 msekEarnings:-11,7 msekEmployees:0ISIN:SE0015961826

Ratios

10-year key figure history for Diagonal Bio turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Diagonal Bio with index and moving average MA50 and MA200.

Stockprice:0,090
MA50:0,17
MA200:0,34
Price/MA200:-73,4 %
RSI (14):52,6
Price/MA50:-47,1 %

Description

Diagonal is a Swedish biotechnology company that develops the platform Panviral - a molecular biological method for detecting and diagnosing small sections of pathogen DNA or RNA. The company is based at Medicon Village in Lund and was founded in 2020. The company aims to use Panviral to revolutionize the diagnosis of pathogenic diseases. Diagonal intends to commercialize fast and highly adaptable products for relevant niches and enable large-scale precision diagnostics for all types of pathogens, ie. infectious agent.

Biotechnology